AnaptysBio: Annual Transition Report (Form 10-KT)
AnaptysBio, Inc. (ANAB) filed a Form 10-KT transition report for the period from January 1, 2026, to June 30, 2026, reflecting a change in its fiscal year end from December 31 to June 30. The company disclosed an aggregate market value of $632.7 million in voting common equity held by non-affiliates as of December 31, 2025, and 29.9 million shares of common stock outstanding as of September 16, 2026. The report includes forward-looking statements and risk factors.
How this was made
The 30-second read
Why it matters
The filing itself does not contain new financial metrics or strategic announcements, but it signals a shift in reporting cadence that could affect future earnings release dates and analyst coverage.
Market read
Primarily relevant to shareholders and analysts monitoring AnaptysBio; limited broader market relevance.
What to watch
Potential changes in timing of upcoming clinical trial updates or partnership announcements that may align with the new reporting calendar.
Background
AnaptysBio filed a Form 10-KT transition report, a regulatory requirement when a company changes its fiscal year. The filing includes standard disclosures and confirms the new fiscal year end of June 30.
Ticker impact
SEC filed AnaptysBio's Form 10-KT transition report, announcing fiscal year change to June 30 and filing requirements for the transition period.
Minimal short-term price effect; potential modest volatility around future quarterly releases.
SEC filings are primary sources; the information is factual and not speculative, but the content is procedural rather than financially material.
Market effects
None significant; the filing is company‑specific and does not alter sector dynamics.
Limited to U.S. biotech investors tracking AnaptysBio.
Low; no broader market impact.
Counterpoint
Investors could view the fiscal year shift as a catalyst for operational flexibility, but without new financial data the effect remains speculative.
Key entities
- companyAnaptysBio, Inc.
Biopharmaceutical company focused on antibody therapeutics.
